AbCellera Biologics Inc.

Listed Company

ABCLCIK 0001703057NasdaqLarge AcceleratedPharmaceutical PreparationsA1CAFY ends Dec 31

Period

FY 2025

Revenue

$75.13M

Net Income

$-146.41M

Total Assets

$1.36B

Equity

$966.90M

Shares Out

305.38M

Op. Cash Flow

$-131.29M

ABCL$6.47+65.90% · past yearDBEQ Basic

Daily closing prices

Business

AbCellera Biologics is a clinical-stage biotechnology company discovering and developing antibody medicines for unmet medical needs. The company offers an integrated antibody drug discovery and development platform targeting complex transmembrane proteins, multispecifics, and antibody-drug conjugates. AbCellera operates internal programs (ABCL635 in Phase 1/2, ABCL575 in Phase 1, and preclinical programs) and partner-initiated programs generating milestone and royalty payments from active collaborations. The company serves the global therapeutic antibody market through direct clinical development and partnerships across oncology, immunology, endocrinology, and other areas.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	75	29	38	485	375
Research and development	187	167	176	108	62
Sales, general and administrative	83	85	75	55	42
Depreciation, amortization, and impairment	22	91	24	28	14
Total operating expenses	292	344	275	269	171
Loss from operations	−217	−315	−237	217	204
Interest income	−28	−38	−42	−16	−3
Grants and incentives	−14	−14	−14	−11	−17
Other (Note 15)	3	−62	−7	4	6
Total other income	−40	−114	−63	−23	−15
Loss before income tax	−178	−200	−174	239	219
Income tax recovery	−31	−38	−28	81	66
Net loss	−146	−163	−146	159	153
Foreign currency translation adjustment	144,000	−3	−329,000	−2	280,000
Comprehensive loss	−146	−166	−147	157	154
Basic (in dollars per share)	−0.49	−0.55	−0.51	0.56	0.56
Diluted (in dollars per share)	−0.49	−0.55	−0.51	0.5	0.48
Basic (in shares)	299	294	289	285	276
Diluted (in shares)	299	294	289	315	318

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	129	156	133	387	476
Marketable securities	405	469	627	500	247
Total cash, cash equivalents, and marketable securities	534	626	761	—	—
Accounts and accrued receivable	58	34	31	39	161
Restricted cash	25	25	25	25	25
Other current assets	111	67	56	75	21
Total current assets	728	751	872	1,025	930
Property and equipment, net	428	340	288	217	—
Intangible assets, net	38	42	120	132	148
Goodwill	48	48	48	48	48
Investments in equity accounted investees	63	82	66	73	50
Other long-term assets	52	97	94	46	31
Total long-term assets	629	609	616	515	389
Total assets	1,357	1,361	1,488	1,541	1,319
Accounts payable and other current liabilities	51	55	50	52	—
Contingent consideration payable	0	8	50	44	23
Deferred revenue	14	14	19	22	8
Total current liabilities	64	77	119	118	121
Operating lease liability	137	61	71	77	36
Deferred government contributions	174	150	96	—	—
Deferred tax liability	9	10	31	33	37
Other long-term liabilities	5	7	6	3	2
Total long-term liabilities	326	228	217	189	172
Total liabilities	390	304	336	308	293
Commitments and contingencies	—	—	—	—	—
Common shares: no par value, unlimited authorized shares at December 31, 2024 and December 31, 2025: 295,757,002 and 300,600,710 shares issued and outstanding at December 31, 2024 and December 31, 2025, respectively	802	777	753	734	722
Additional paid-in capital	198	166	121	74	35
Accumulated other comprehensive loss	−4	−4	−2	−1	280,000
Accumulated earnings (deficit)	−29	117	280	426	268
Total shareholders' equity	967	1,056	1,152	1,233	1,026
Total liabilities and shareholders' equity	1,357	1,361	1,488	1,541	1,319

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−146	−163	−146	159	153
Depreciation of property and equipment	18	13	13	9	4
Amortization and impairment of intangible assets	4	78	12	19	10
Amortization of operating lease right-of-use assets	7	6	6	5	3
Stock-based compensation	56	68	64	49	31
Fair value (gain) loss on contingent consideration and investments	5	−65	−8	3	—
Other	−3	−20	2	3	1
Research fees and grants receivable	−56	−75	−46	−23	−37
Income taxes (payable) receivable	−30	7	30	−89	−14
Accounts payable and accrued liabilities	3	11	−15	−2	—
Deferred revenue	−2	−8	−14	6	9
Deferred grant income	−4	34	40	9	31
Other assets	17	6	18	−1	−3
Net cash used in operating activities	−131	−109	−44	277	245
Purchases of property and equipment	−43	−78	−77	−71	−58
Purchase of marketable securities	−436	−765	−1,022	−764	−275
Proceeds from marketable securities	506	938	911	511	28
Receipt of grant funding	21	36	25	16	33
Distribution from equity accounted investees	30	0	0	—	—
Investment in and loans to equity accounted investees	−7	−20	−14	−26	−30
Proceeds from repayment of loan from joint venture partner	33	0	0	—	—
Long-term investments and other assets	−17	11	−45	−17	—
Net cash provided by (used in) investing activities	88	121	−221	−353	−332
Payment of liability for in-licensing agreement and other	−16	−729,000	−1	−4	—
Proceeds from long-term liabilities and other	30	13	12	3	5
Net cash provided by financing activities	14	13	10	−2	−4
Effect of exchange rate changes on cash and cash equivalents	1	−3	589,000	−10	−1
Increase (decrease) in cash and cash equivalents	−28	23	−254	−86	−93
Property and equipment in accounts payable	2	13	14	6	5
Right-of-use assets obtained in exchange for operating lease obligation	76	2	1	51	37

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AbCellera Biologics Inc.'s CIK number?

AbCellera Biologics Inc.'s SEC CIK number is 0001703057 (1703057). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AbCellera Biologics Inc.'s SEC filings?

All of AbCellera Biologics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AbCellera Biologics Inc. last report earnings?

AbCellera Biologics Inc. (ABCL) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001703057-26-000027). This is AbCellera Biologics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is AbCellera Biologics Inc.'s most recent earnings 8-K?

AbCellera Biologics Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001703057-26-000027. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AbCellera Biologics Inc.'s latest earnings 8-K →
Look up any company's CIK number →